Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.38 |
| ▸ | RXRA | P19793 | 9/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 9/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 9/20 | 0.36 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29974801 | 1.00 | MBOAT4 (0.42) | MBOAT4HCRTR1HCRTR2RXRAGRIN1 | |
| SCHEMBL19555693 | 0.81 | MBOAT4 (0.45) | MBOAT4HCRTR1HCRTR2RXRAGRIN1 | |
| SCHEMBL18378650 | 0.81 | MBOAT4 (0.45) | MBOAT4HCRTR1HCRTR2RXRAGRIN1 | |
| SCHEMBL2895609 | 0.81 | MBOAT4 (0.42) | MBOAT4HCRTR1HCRTR2RXRAGRIN1 | |
| SCHEMBL19771881 | 0.77 | MBOAT4 (0.43) | MBOAT4HCRTR1HCRTR2RXRAGRIN1 | |
| SCHEMBL30106088 | 0.76 | ATM (0.44) | MBOAT4HCRTR1HCRTR2ALKBH1NPC1 | |
| SCHEMBL27847702 | 0.76 | ATM (0.44) | MBOAT4HCRTR1HCRTR2ALKBH1NPC1 | |
| SCHEMBL28129456 | 0.75 | MBOAT4 (0.41) | MBOAT4HCRTR1HCRTR2RXRAGRIN1 | |
| SCHEMBL23224312 | 0.75 | MBOAT4 (0.39) | MBOAT4RXRAGRIN1GRIN2BCCR1 | |
| SCHEMBL30015156 | 0.75 | CA12 (0.40) | MBOAT4MEN1KMT2ACCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3976617-B1 | FUSED HETEROCYCLIC DERIVATIVES | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2025-04-23 | — | — | EP | disclosed |
| US-9868748-B2 | Thiazolopyrrolidine inhibitors of ROR- γ | VITAE PHARMACEUTICALS, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-20170008910-A1 | THIAZOLOPYRROLIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2017-01-12 | — | — | US | disclosed |
| US-20170008910-A1 | THIAZOLOPYRROLIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2017-01-12 | — | — | US | disclosed |
| EP-2991994-A1 | THIAZOLOPYRROLIDINE INHIBITORS OF ROR-GAMMA | Vitae Pharmaceuticals, Inc. (US) | 2016-03-09 | — | — | EP | disclosed |
| US-9242970-B2 | Lactam derivatives useful as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-01-26 | — | — | US | disclosed |
| EP-2638008-B1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-07-01 | — | — | EP | disclosed |
| WO-2014179564-A1 | THIAZALOPYRROLIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | WO | disclosed |
| WO-2014179564-A1 | THIAZALOPYRROLIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | WO | disclosed |
| EP-2638008-A1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2013-09-18 | — | — | EP | disclosed |
| US-20130237525-A1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-09-12 | — | — | US | disclosed |
| WO-2012063207-A1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237525-A1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | MBOAT4 1555/4885HCRTR1 2/4885HCRTR2 1/4885 |
| US-20170008910-A1 | THIAZOLOPYRROLIDINE INHIBITORS OF ROR-GAMMA | RORC, RORB, RORA | MBOAT4 3758/4885HCRTR1 2007/4885HCRTR2 2091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.